Celldex Therapeutics (CLDX) Capital Expenditures (2010 - 2026)

Celldex Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 518.49% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $4.1 million (up 122.17% YoY), while the FY2025 annual figure was $2.7 million, up 41.43% from the prior year.
• Capital Expenditures was $1.6 million for Q1 2026 at Celldex Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q1 2026 to a low of $157000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $583411.8 across 5 years, with a median of $545000.0 in 2024.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures plunged 54.49% in 2023, then soared 518.49% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $235000.0 in 2022, then surged by 183.4% to $666000.0 in 2023, then climbed by 13.51% to $756000.0 in 2024, then jumped by 69.44% to $1.3 million in 2025, then climbed by 27.95% to $1.6 million in 2026.
• The last three Capital Expenditures figures came in at $1.6 million (Q1 2026), $1.3 million (Q4 2025), and $440000.0 (Q3 2025), per Business Quant data.